Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
TTTSF (.0553): Share price spiked 55% on Canadian exchange in the last half hour Friday on 1,470,000 volume. Spiked 53% in U.S. on a mere 121,000 volume.
ROIV: On 11/8, Wainwright initiates Buy rating at $14.
ROIV (8.40):Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
https://finance.yahoo.com/news/roivant-report-financial-results-quarter-214500959.html
META etf includes all the heavyweight names to move the metaverse forward. I bought some shares after playing the options a couple of weeks ago, right before Facebook announced the name change. It was hysterical watching all the volume pour into META as some folks erroneously thought they were buying Facebook, but with the new Facebook name! (META symbol)
Bigger patent problems for Moderna that just ABUS!
https://www.nytimes.com/2021/11/09/us/moderna-vaccine-patent.html
WASHINGTON — Moderna and the National Institutes of Health are in a bitter dispute over who deserves credit for inventing the central component of the company’s powerful coronavirus vaccine, a conflict that has broad implications for the vaccine’s long-term distribution and billions of dollars in future profits.
The vaccine grew out of a four-year collaboration between Moderna and the N.I.H., the government’s biomedical research agency — a partnership that was widely hailed when the shot was found to be highly effective. A year ago this month, the government called it the “N.I.H.-Moderna Covid-19 vaccine.”
CLVR: Added $7.50 calls on this news. Fins tomorrow.
https://born2invest.com/articles/medical-cannabis-to-be-sold-freely-drugstores-across-colombia/
That story showed up about 15 minutes ago, even though it was originally reported a couple of weeks ago.
Check out other members of APAC.
VeChain
https://investorplace.com/2021/11/vechain-price-predictions-how-high-can-the-vet-crypto-go-in-2021-2023/
Laava
https://wineindustryadvisor.com/2021/06/03/vinsent-laava-team-up-nfts-wine
Fresh Supply Company
https://freshsupplyco.com/
Source Certain International
https://www.sourcecertain.com/news
Escavox
https://www.foodanddrinkbusiness.com.au/news/automated-calculator-saves-shelf-life-guesswork
TTTSF (.0401): TruTrace Technologies Joins the APAC Provenance Alliance to Expand Use of Blockchain Technology to Protect and Authenticate Products
7:00 AM ET 11/8/21 | BusinessWire
North American company joins a consortium of technology and service providers within the global food supply chain industry
TORONTO--(BUSINESS WIRE)--November 08, 2021--
TruTrace Technologies (CSE: TTT; OTCQB: TTTSF), developer of a fully-integrated blockchain platform for the legal cannabis, food, and pharmaceutical industries, is proud to announce that it has recently joined APAC (Asia Pacific) Provenance, which is an industry alliance that helps exporters digitally enable and scientifically prove the provenance, traceability and authenticity of their products.
APAC Provenance combines technology and research with established industry solutions, suppliers, and standards, to deliver practical solutions that strengthen the integrity of export supply chains. Members include industry leaders such as Fresh Supply Co, Source Certain International, Matthews Australasia, Opal Packaging, Escavox and Laava; as well as blockchain leader VeChain and many specialized marketing and packaging service providers.
"Over the past several years we have seen a change in the way that we engage with products and how interconnected we are throughout the world, " stated Robert Galarza, CEO of TruTrace. "To tackle the challenges of the complex global supply chain we must take a collaborative and cooperative approach and we are honoured to join such a remarkable group of companies and are excited to bring our value to the overall mission of APAC Provenance."
As supply chains continue to be stressed throughout the world, particularly within international exports, there has been a push for collaboration and innovation to mitigate these challenges. The alliance aims to directly meet these needs, as well as the ever-changing habits of customers who are demanding greater access to healthy, nutritious, and high-quality food and beverages. By combining the resources of all members, the alliance aims to bring together best in class technologies and services to support a blockchain-enabled and consumer verifiable supply chain. With transparency and provenance being a cornerstone of the alliance, there is significant value to high quality producers and manufacturers who want to engage directly with customers and share a genuine and engaging story about their products.
APAC Provenance Co-Founder and Laava ID Joint-CEO Gavin Ger said, "On behalf of APAC Provenance, I'm thrilled to see TruTrace join the alliance. Our fellow members and customers in the region are always striving to improve their track and trace and supply chain automation capabilities. TruTrace delivers these capabilities, as well as an incredible depth of capability in product assurance and lab/test report management, plus traceability of strains and cultivars -- to create a truly end-to-end solution for APAC Provenance clients. We look forward to exploring joint opportunities together for the benefit of industry and consumers."
About TruTrace Technologies
TruTrace Technologies is the developer of fully integrated software, secured on a blockchain infrastructure, that gives clients' the ability to store, manage, share and immediately access quality assurance and testing details, COAs, as well as motion and movement intelligence on inventory. The platform was specifically designed to power the traceability of testing standards within the legal cannabis, nutraceutical, food and pharmaceutical space with a focus on the authentication of source materials or ingredients used in formulation. For more information, please visit www.trutrace.co.
About APAC Provenance
Asia Pacific Provenance is an industry alliance which helps exporters digitally enable and scientifically prove the provenance, traceability and authenticity of their products, and tell the stories behind their brands. By combining the best capabilities of a range of key technologies, products and services, APAC Provenance offers exporters an integrated, yet modular suite of technology capabilities across the traceability, provenance, brand protection, marketing and packaging ecosystem.
Follow TruTrace:
LinkedIn: https://www.linkedin.com/company/trutracetech
Twitter: https://twitter.com/trutracetech
Instagram: https://www.instagram.com/trutracetechnologies
Forward Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon TruTrace current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy.
The forward-looking information in this news release is based upon the expectations, estimates, projections, assumptions and views of future events which management believes to be reasonable in the circumstances. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact. Forward-looking information in this news release include, but are not limited to, statements with respect to internal expectations, expectations with respect to actual production volumes, expectations for future capacity for growth and the completion of any capital project or expansions. Forward-looking information necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the Asia-Pacific market generally; the global food industry generally; the ability of TruTrace to implement its business strategies; the COVID-19 pandemic; competition; and other risks.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, TruTrace does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for TruTrace to predict all such factors. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in TruTrace's disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE CANADIAN SECURITIES EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211108005273/en/
CONTACT: Media Contacts:
Corey Herscu for TruTrace Technologies
corey@verbfactory.com
+1 416-300-3030 (North America)
Gavin Ger for APAC Provenance
gavin@laava.id
+61 (0)402-023-703 (ANZ)
LinkedIn: https://www.linkedin.com/company/apacprovenance
SOURCE: TruTrace Technologies
Copyright Business Wire 2021
> Dow Jones Newswires
November 08, 2021 07:00 ET (12:00 GMT)
ROIV: Another "outperform" added today.
SVB Leeriink.
https://www.benzinga.com/stock/roiv/ratings
From last week:https://www.fool.com/investing/2021/10/26/why-roivant-sciences-stock-is-soaring-today/
ROIV up 20% pm. Not because of ABUS patent, but on 3 analysts jumping on board with targets between $10 and $15.
https://www.streetinsider.com/Analyst+Comments/Roivant+Sciences+%28ROIV%29+Stock+Surges+20%25+as+Three+Street+Firms+Initiate+Coverage+With+Positive+Ratings/19104874.html
ROIV up 20% pm. Not because of ABUS patent, but on 3 analysts jumping on board with targets between $10 and $15.
ROIV up 12% . For the past few days, every time ABUS fails to get a verdict, ROIV spikes around 10:30-11:00. Today is more pronounced, though ROIV has been up since pre-market.
Sio Gene Therapies Announces Reorganization of R&D Group
https://www.globenewswire.com/news-release/2021/10/21/2318825/0/en/Sio-Gene-Therapies-Announces-Reorganization-of-R-D-Group.html
SIOX key quotes
https://pulse2.com/sio-gene-therapies-nasdaq-siox-stock-why-it-increased-today/
KEY QUOTES:
“Our team continues to lead the industry in the development of a new, potentially disease-modifying therapeutic option for GM1 gangliosidosis. We are extremely proud of these data, representing our broadest dataset generated thus far, which support a dose response and a favorable safety and tolerability profile at both low and high doses. We observed dose-dependent responses in two key biomarkers, serum ß-galactosidase and cerebrospinal fluid (CSF) GM1 ganglioside, including normalization of both biomarkers in the high-dose cohort. Taken together, six out of seven patients show no evidence of overt disease progression at the latest timepoint assessed, and we now have a better understanding of the clinical measures that may serve as important indicators of efficacy. Based on the results of this ongoing study, we are working on the continued development of AXO-AAV-GM1 and plan to engage the FDA to discuss further development, recognizing that there is currently no approved therapy available for GM1 patients.”
— Gavin Corcoran, M.D., Chief R&D Officer of Sio Gene Therapies
“I have dedicated my career to the care of patients with GM1 gangliosidosis and to research efforts in the search for a functional cure. The biomarker dose response and favorable safety profile is a remarkable finding for the gene therapy field. I am excited about the potential impact that AXO-AAV-GM1 may have on the lives of these children and their families. I look forward to seeing the longer-term data, where we may have a chance to see not only durable disease stabilization, but possibly even improvement.”
I couldn't agree with you more, georgejjl!
SIOX: Sio Gene Therapies Announces Granting of FDA Fast Track Designation for Investigational AXO-AAV-GM1 (AAV9-GLB1) Gene Therapy in Patients with GM1 Gangliosidosis
https://finance.yahoo.com/news/sio-gene-therapies-announces-granting-120000153.html
SIOX receives FDA Fast Track Designation. Up 13% pm.
ROIV owns 25% stake in SIOX.
https://www.globenewswire.com/news-release/2021/10/21/2318287/0/en/Sio-Gene-Therapies-Announces-Granting-of-FDA-Fast-Track-Designation-for-Investigational-AXO-AAV-GM1-AAV9-GLB1-Gene-Therapy-in-Patients-with-GM1-Gangliosidosis.html
ROIV-related SIOX receives FDA Fast Track Designation for drug. ROIV owns 25% of SIOX.
https://www.globenewswire.com/news-release/2021/10/21/2318287/0/en/Sio-Gene-Therapies-Announces-Granting-of-FDA-Fast-Track-Designation-for-Investigational-AXO-AAV-GM1-AAV9-GLB1-Gene-Therapy-in-Patients-with-GM1-Gangliosidosis.html
SIOX up 12% pm. Positive results announced.
Presentation today.
https://www.globenewswire.com/news-release/2021/10/21/2318079/0/en/Sio-Gene-Therapies-Announces-Positive-Interim-Safety-and-Biomarker-Data-from-Ongoing-Phase-1-2-Clinical-Study-of-AXO-AAV-GM1-Gene-Therapy-in-GM1-Gangliosidosis.html
You've been missing lately. Thought maybe MWM had you stashed in a trunk somewhere!
SIOX (2.32): Volume spurt yesterday. Presentation tomorrow.
No press release yet.
https://www.globenewswire.com/news-release/2021/10/04/2307996/0/en/UPDATE-Sio-Gene-Therapies-to-Present-New-Data-at-the-European-Society-of-Gene-and-Cell-Therapy-Virtual-Congress-2021.html
Abstracts out from ESGCT:
Collaborative Virtual Congress
19–22 October 2021
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts
SIOX(2.26) today: HC Wainwright reiterates $8 target, Buy rating,
SIOX today: HC Wainwright reiterates Buy rating, target $8.00
Great volume going into Thursday's presentations.
SIOX pre-market move. ROIV owns 25%.
No press release yet.
https://www.globenewswire.com/news-release/2021/10/04/2307996/0/en/UPDATE-Sio-Gene-Therapies-to-Present-New-Data-at-the-European-Society-of-Gene-and-Cell-Therapy-Virtual-Congress-2021.html
Abstracts out from ESGCT:
Collaborative Virtual Congress
19–22 October 2021
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts
SIOX pre-market move. ROIV owns 25%.
https://www.globenewswire.com/news-release/2021/10/04/2307996/0/en/UPDATE-Sio-Gene-Therapies-to-Present-New-Data-at-the-European-Society-of-Gene-and-Cell-Therapy-Virtual-Congress-2021.html
Abstracts out from ESGCT:
Collaborative Virtual Congress
19–22 October 2021
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts
ROIV stake in SIOX
https://investors.siogtx.com/investors/stock-information/institutional-ownership
SIOX: Abstracts out. Nice PM volume.
https://www.liebertpub.com/doi/full/10.1089/hum.2021.29180.abstracts
SIOX: Nice end of day flurry to close Green.
RCON making nice early move.
Two ROIV executives sit on ABUS Board of Directors
Frank Torti MD
Chairman
Dr. Torti has served as Chairperson of Arbutus’s board of directors since November 2018. Dr. Torti has served as the Vant Chair of Roivant Sciences, Inc. (RSI) since January 2020. In this capacity he serves as Chairperson of the boards of directors of the biopharmaceutical companies in the Roivant family and is responsible for the operations and management of those companies. He previously served as Vant Investment Chair of RSI, from August 2018 to December 2019.
Eric Venker M.D., Pharm.D.
Independent Director
Dr. Venker has served on Arbutus’s board of directors since February 2020. Dr. Venker has served as Chief Operating Officer of Roivant Sciences, Inc. (RSI) since November 2018. From October 2017 to October 2018, he served as Chief of Staff to RSI’s Chief Executive Officer, and from 2014 to 2015 as an Analyst at RSI.
ABUS still flying at 7:44 pm. Touched 4.70 AH.
TTTSF: How Blockchain and Molecular Tagging Can Support The Growth Of The Medical Cannabis Industry
https://businesscann.com/how-blockchain-and-molecular-tagging-can-support-the-growth-of-the-medical-cannabis-industry/?fbclid=IwAR0-jo17hmQ9S_TlImtbqFYwmPmDXG3XMn2_3u4ir72OtmnIIjeXGNWzh_c
ABUS and ROIV moving together.
10/18:ROIV to convert ABUS Preferred to common shares.
Page 44 https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=115698797&type=PDF&symbol=ABUS&companyName=Arbutus+Biopharma+Corporation&formType=10-K&formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2021-03-04&CK=1447028
Quote:
Entities associated with Roivant Sciences Ltd. (“Roivant”) collectively held as a group approximately 23% of our outstanding common shares as of March
1, 2021. In addition, in October 2017, we issued 500,000 Series A participating convertible preferred shares (“Preferred Shares”) to Roivant for gross
proceeds of $50.0 million. We issued a second tranche of 664,000 Preferred Shares to Roivant in January 2018 for gross proceeds of $66.4 million. The
Preferred Shares are non-voting and are convertible into common shares at a conversion price of $7.13 per share (which represents a 15% premium to the
closing price of $6.20 per share on October 16, 2017). The Preferred Shares are currently not convertible into common shares. The purchase price for the
Preferred Shares plus an amount equal to 8.75% per annum, compounded annually, will be subject to mandatory conversion into approximately 23 million
common shares on October 18, 2021 (subject to limited exceptions in the event of certain fundamental corporate transactions relating to our capital
structure or assets, which would permit earlier conversion at
Roivant’s option). Assuming the Preferred Shares were converted as of March 1, 2021, Roivant would have held approximately 39 million common shares,
or, 32%, of our outstanding common shares. Roivant has agreed to a four year lock-up period and standstill period whereby, pursuant to the standstill,
Roivant will not acquire greater than 49.99% of our common shares or securities convertible into common shares. Both the lockup and standstill periods
expire on October 18, 2021. Following the expiration of the standstill period, Roivant will no longer be contractually prohibited from acquiring control of
our company
10/8: ROIV files S-8 for 2021 EQUITY INCENTIVE PLAN
https://www.sec.gov/Archives/edgar/data/1635088/000095010321015700/dp159512_s8.htm
5/21: ROIV canceled Option to sell Genevant stake
From 10-Q
On December 27, 2019
"Additionally, in connection with the Sumitomo Transaction Agreement, RSL (i) granted Sumitomo options to purchase all, or in the case of Dermavant, 75%, of RSL’s ownership interests in six other subsidiaries (Dermavant, Genevant Sciences Ltd. (“Genevant”), Lysovant Sciences Ltd., Metavant Sciences Ltd., Roivant Asia Cell Therapy Holdings Ltd., and Sinovant Sciences HK Limited (collectively, the “Option Vants”)."
Then:
In May 2021, the Company entered into an Asset Purchase Agreement with Sumitomo and its subsidiary Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. (“SPC”) (the “Asset Purchase Agreement”). The transactions contemplated by the Asset Purchase Agreement closed in June 2021. Pursuant to the Asset Purchase Agreement: (i) Sumitomo terminated all of its existing options to acquire the Company’s equity interests in the Option Vants (the “Sumitomo Options”); (ii) the Company transferred and assigned to SPC all of its intellectual property, development and commercialization rights for (a) lefamulin in Mainland China, Taiwan, Hong Kong, and Macau (collectively “Greater China”), (b) vibegron in Mainland China, (c) rodatristat ethyl in Greater China and South Korea and (d) RVT-802 in Greater China and South Korea; (iii) Sumitomo agreed to pay the Company $5.0 million in cash; and (iv) Sumitomo entered into an agreement with the Company to pursue future collaborations with Genevant. The Company received the cash payment, net of certain withholding taxes, in August 2021. The Company recorded a gain on the termination of the Sumitomo Options of $66.5 million, consisting of the fair value of the Sumitomo Options on the date of termination and the expected cash payment, in the accompanying condensed consolidated statements of operations for the three months ended June 30, 2021
ABUS: A look at the biopharmas developing new treatments for liver diseases
https://seekingalpha.com/news/3750999-a-look-at-the-biopharmas-developing-new-treatments-for-liver-diseases?utm_campaign=rta-stock-news&utm_content=link-1&utm_medium=email&utm_source=seeking_alpha&utm_term=RTA+News+Smart
Biotech stocks are doing something that could result in a double-digit rally, trader says
https://www.cnbc.com/2021/10/08/biotechs-latest-trend-could-result-in-double-digit-rally-trader.html
Tensions grow between Moderna, White House over vaccine production
The Biden administration has urged Moderna for months to increase its production domestically.
https://www.politico.com/news/2021/10/07/biden-admins-moderna-international-donations-515537